

研究成果の刊行に関する一覧表

書籍（外国語）

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ

雑誌（外国語）

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Minchenko OH, Tsuchihara K, <u>Esumi H</u> , et. al.	Mechanisms of regulation of PFKFB expression in pancreatic and gastric cancer cells.	World J Gastroenterol	20(38)	13705-17	2014
Suzuki A, Makinoshima H, Wakamatsu H, <u>Esumi H</u> , et. al.	Aberrant transcriptional regulations in cancers: genome, transcriptome and epigenome analysis of lung adenocarcinoma cell lines.	Nucleic Acids Res	42(22)	13557-72	2014
Obata Y, Toyoshima S, Wakamatsu E, <u>Esumi H</u> , et. al.	Oncogenic Kit signals on endolysosomes and endoplasmic reticulum are essential for neoplastic mast cell proliferation.	Nat Commun.	5	5715	2014
Makinoshima H, Takita M, Matsumoto S, <u>Esumi H</u> , et. al.	Epidermal growth factor receptor (EGFR) signaling regulates global metabolic pathways in EGFR-mutated lung adenocarcinoma.	J Biol Chem	289(30)	20813-23	2014

<u>Esumi H.</u>	"S'ils n'ont pas de pain, qu'ils mangent de la brioche." Focus on "anaerobic respiration sustains mitochondrial membrane potential in a prolyl hydroxylase pathway-activated cancer cell line in a hypoxic microenvironment".	American Journal of Physiology Cell Physiology	306	C320-321	2014
Kami K, Fujimori T, Sato H, <u>Esumi H.</u> , et. al.	Metabolomic profiling of lung and prostate tumor tissues by capillary electrophoresis time-of-flight mass spectrometry	Metabolomics : Official journal of the Metabolomic Society	9	444-453	2013
Kudou N, Taniguchi A, Sugimoto K, <u>Esumi H.</u> , et. al.	Synthesis and antitumor evaluation of arctigenin derivatives based on antiausterity strategy	European journal of medicinal chemistry	60	76-88	2013
Ueda JY, Athikomkulchai S, Miyatake R, <u>Esumi H.</u> , et. al.	(+)-Grandifloracin, an antiausterity agent, induces autophagic PANC-1 pancreatic cancer cell death	Drug design, development and therapy	8	39-47	2014
Suzuki M., Makinoshima H., Matsumoto S., <u>Esumi H.</u> , et. al.	Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo	Cancer Science	104(7)	896-903	2013
Suzuki A, Mimaki S, Yamane Y, <u>Esumi H.</u> , et. al.	Identification and characterization of cancer mutations in Japanese lung adenocarcinoma without sequencing of normal tissue counterparts	PLoS One	8(9)	e73484	2013
Nasuno T, Mimaki S, Okamoto M, <u>Esumi H.</u> , et. al.	Effect of a poly(ADP-ribose) polymerase-1 inhibitor against esophageal squamous cell carcinoma cell lines.	Cancer Science	105(2)	202-210	2014

Awale S, Kato M, Dibwe DF, <u>Esumi H</u> , et. al.	Antiausterity Activity of Arctigenin Enantiomers: Importance of (2R, 3R)-absolute configuration.	Nat. Prod Commun	9(1)	79-82	2014
Yamashita T, Uehara S, Udagawa N, <u>Esumi H</u> , et. al.	Arctigenin inhibits osteoclast differentiation and function by suppressing both calcineurin-Dependent and osteoblastic cell-dependent NFATc1 pathways	PloS one	9(1)	e85878	2014
Kudou N, Taniguchi A, Sugimoto K, <u>Esumi H</u> , et. al.	Synthesis and antitumor evaluation of arctigenin derivatives based on antiausterity strategy.	Eur J Med Chem	60	76-88	2012
Owada S, Shimoda Y, Tsuchihara K, <u>Esumi H</u> , et. al.	Critical role of H ₂ O ₂ generated by NOX4 during cellular response under glucose deprivation.	PLoS One	8(3)	e56628	2013
Kami K, Fujimori T, Sato H, <u>Esumi H</u> , et. al.	Metabolomic profiling of lung and prostate tumor tissues by capillary electrophoresis time-of-flight mass spectrometry.	Metabolomics	9(2)	444-453	2012
Yamagata Y, Aikou S, Fukushima T, Kataoka H, <u>Esumi H</u> , et. al.	Loss of HGF activator inhibits foveolar hyperplasia induced by oxyntic atrophy without altering gastrin levels.	Am J Physiol Gastrointest Liver Physiol	303(11)	G1254-61	2012
Sakai C, Tomitsuka E, <u>Esumi H</u> , et. al.	Mitochondrial fumarate reductase as a target of chemotherapy: from parasites to cancer cells.	Biochim Biophys Acta	1820(5)	643-51	2012
Inazuka F, Sugiyama N, Tomita M, <u>Esumi H</u> , et. al.	Muscle-specific knockout of NUA family SNF1-like kinase 1 (NUAK1) prevents high fat diet-induced glucose intolerance.	J Biol Chem	287(20)	16379-89	2012

Magolan J, Adams NB, Onozuka H, <u>Esumi H</u> , et al.	Synthesis and evaluation of anticancer natural product analogues based on angelmarin: targeting the tolerance towards nutrient deprivation.	ChemMedChem	7(5)	766-70	2012
Tomitsuka E, Kita K, <u>Esumi H</u>	An anticancer agent, pyrvinium pamoate inhibits the NADH-fumarate reductase system-a unique mitochondrial energy metabolism in tumour microenvironments.	J Biochem	152(2)	171-83	2012
Kawamoto Y, Tsuchihara K, Yoshino T, <u>Esumi H</u> , et al.	KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer.	Br J Cancer	107(2)	340-4	2012
Okusaka T, <u>Ikedaka M</u> , Fukutomi A, Ioka T, et al.	Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer.	Cancer Sci.	105	1321-6	2014
Sugimoto M, Mitsunaga S, Yoshikawa K, <u>Ikeda M</u> , et al.	Prognostic impact of M2 macrophages at neural invasion in patients with invasive ductal carcinoma of the pancreas.	Eur J Cancer	50	1900-8	2014
Okusaka T, <u>Ikedaka M</u> , Fukutomi A, Kobayashi Y, et al.	Safety, Tolerability, Pharmacokinetics and Antitumor Activity of Ganitumab, an Investigational Fully Human Monoclonal Antibody to Insulin-like Growth Factor Type 1 Receptor, Combined with Gemcitabine as First-line Therapy in Patients with Metastatic Pancreatic Cancer: A Phase 1b Study.	Jpn J Clin Oncol	44	442-7	2014
Shinohara A, <u>Ikeda M</u> , Okuyama H, Kobayashi M, et al.	Efficacy of Prophylactic Minocycline Treatment for Skin Toxicities Induced by Erlotinib Plus Gemcitabine in Patients with Advanced Pancreatic Cancer: A Retrospective Study.	Am J Clin Dermatol	in press	PMID: 25687689	2015

<u>Ikeda M</u> , Ioka T, Ito Y, Yonemoto N, et. al.	A Multicenter Phase II Trial of S-1 With Concurrent Radiation Therapy for Locally Advanced Pancreatic Cancer.	Int J Radiat Oncol Biol Phys.	85	163-169	2013
Ueno H, Ioka T, <u>Ikeda M</u> , Ohkawa S, et. al.	Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study.	J Clin Oncol.	31	1640-8	2013
Mitsunaga S, <u>Ikeda M</u> , Shimizu S, Ohno I, et. al.	Serum levels of IL-6 and IL-1 β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer	Br J Cancer	108	2063-9	2013
Otsuka T, Morizane C, Nara S, <u>Ikeda M</u> , et. al.	Gemcitabine in Patients With Intraductal Papillary Mucinous Neoplasm With an Associated Invasive Carcinoma of the Pancreas.	Pancreas	42	889-92	2013
Taniyama TK, Morizane C, Nakachi K, <u>Ikeda M</u> , et. al.	Treatment outcome for systemic chemotherapy for recurrent pancreatic cancer after postoperative adjuvant chemotherapy.	Pancreatology	12(5)	428-33	2012
<u>Ikeda M</u> , Ioka T, Ito Y, Yonemoto N, et. al.	A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer.	Int J Radiat Oncol Biol Phys	85(1)	163-9	2012
Imoto A, Mitsunaga S, Inagaki M, Aoyagi K, Sasaki H, <u>Ikeda M</u> , et. al.	Neural invasion induces cachexia via astrocytic activation of neural route in pancreatic cancer.	Int J Cancer.	131(12)	2795-807	2012
Morizane C, Okusaka T, Ueno H, <u>Ikeda M</u> , et. al.	Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients.	Cancer Chemother Pharmacol	69(4)	957-64	2012

<u>Ueno H</u> , Ioka T, Ikeda M, et al	Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.	J Clin Oncol	31	1640-8	2013
Kondo S, <u>Ueno H</u> , Hosoi H, et al	Clinical impact of pentraxin family expression on prognosis of pancreatic carcinoma	Br J Cancer	109	739-46	2013
Lin Y, Ueda J, Yagyu K, <u>Ishii H</u> , et. al.	Association between variations in the fat mass and obesity-associated gene and pancreatic cancer risk: a case-control study in Japan	BMC Cancer	13	337	2013
Matsuyama M, <u>Ishii H</u> , Kuraoka K, Yukisawa S, et. al.	Ultrasound-guided vs endoscopic ultrasound-guided fine-needle aspiration for pancreatic cancer diagnosis	World J Gastroenterol	19(15)	2368-73	2013
<u>Okusaka T</u> , Ueno M, Sato T, Heike Y	Possibility of immunotherapy for biliary tract cancer: how do we prove efficacy? Introduction to a current ongoing phase I and randomized phase II study to evaluate the efficacy and safety of adding Wilms tumor 1 peptide vaccine to gemcitabine and cisplatin for the treatment of advanced biliary tract cancer (WT-BT trial).	J Hepatobiliary Pancreat Sci	19(4)	314-8	2012
<u>Okusaka T</u> , Ueno H, <u>Ikeda M</u> , et. al.	Phase I study of TAC-101, an oral synthetic retinoid, in Japanese patients with advanced hepatocellular carcinoma.	Cancer Sci	103(8)	103(8)	2012

<u>Okusaka T</u> , Kasugai H, <u>Ishii H</u> , Kudo M, et. al.	A randomized phase II trial of intra-arterial chemotherapy using SM-11355 (Miriplatin) for hepatocellular carcinoma.	Invest New Drugs	30(5)	2015-25	2012
Morizane C, <u>Okusaka T</u> , Ueno H, Kondo S, Ikeda M, et. al.	Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients.	Cancer Chemother Pharmacol	69(4)	957-64	2012
Kondo S, Ojima H, Tsuda H, <u>Okusaka T</u> , et. al.	Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma.	Int J Clin Oncol	18(2)	207-13	2012
Kondo S, Ueno H, Hashimoto J, <u>Okusaka T</u> , et. al.	Circulating endothelial cells and other angiogenesis factors in pancreatic carcinoma patients receiving gemcitabine chemotherapy.	BMC Cancer	12	268	2012
Fukutomi A, Furuse J, <u>Okusaka T</u> , Miyazaki M, et. al.	Effect of biliary drainage on chemotherapy in patients with biliary tract cancer: an exploratory analysis of the BT22 study.	HPB (Oxford)	14(4)	221-7	2012
Morofuji N, Ojima H, Onaya H, <u>Okusaka T</u> , et. al.	Macrophage-capping protein as a tissue biomarker for prediction of response to gemcitabine treatment and prognosis in cholangiocarcinoma.	J Proteomics	75(5)	1577-89	2012
Naganuma A, Miyahara H, Morizane C, <u>Okusaka T</u>	Successful control of intractable hypoglycemia using radiopharmaceutical therapy with strontium-89 in a case with malignant insulinoma and bone metastases.	Jpn J Clin Oncol	42(7)	640-5	2012
Egawa S, Tomah H, Ohigashi H, <u>Okusaka T</u> , et. al.	Japan Pancreatic Cancer Registry; 30th Year Anniversary: Japan Pancreas Society.	Pancreas	41(7)	985-92	2012

Kido H, Morizane C, Tamura T, <u>Okusaka T</u> , et. al.	Gemcitabine-induced pleuropericardial effusion in a patient with pancreatic cancer.	Jpn J Clin Oncol	42(9)	845-50	2012
Fujimoto A, Totoki Y, Abe T, <u>Okusaka T</u> , et. al.	Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators.	Nat Genet	44(7)	760-4	2012
Terashima T, Morizane C, Hirao N, <u>Okusaka T</u> , et. al.	Comparison of chemotherapeutic treatment outcomes of advanced extrapulmonary neuroendocrine carcinomas and advanced small-cell lung carcinoma.	Neuroendocrinology	96(4)	324-32	2012
Otsuka T, Morizane C, Nara S, Ueno H, <u>Okusaka T</u> , et. al.	Gemcitabine in patients with intraductal papillary mucinous neoplasm with an associated invasive carcinoma of the pancreas.	Pancreas	42(5)	889-92	2013
Ito T, <u>Okusaka T</u> , <u>Ikeda M</u> , Igarashi H, et. al.	Everolimus for advanced pancreatic neuroendocrine tumours: a subgroup analysis evaluating Japanese patients in the RADIANT-3 trial.	Jpn J Clin Oncol	42(10)	903-11	2012
Taniyama TK, Morizane C, <u>Ikeda M</u> , <u>Okusaka T</u> , et. al.	Treatment outcome for systemic chemotherapy for recurrent pancreatic cancer after postoperative adjuvant chemotherapy.	Pancreatology	12(5)	428-33	2012
Shiba S, Kondo S, <u>Ikeda M</u> , <u>Okusaka T</u> , et. al.	Hepatitis B Virus Reactivation during Treatment with Multi-Tyrosine Kinase Inhibitor for Hepatocellular Carcinoma.	Case Rep Oncol	5(3)	515-9	2012

Honda K, <u>Okusaka T</u> , Felix K, Nakamori S, et. al.	Altered plasma apolipoprotein modifications in patients with pancreatic cancer: protein characterization and multi-institutional validation.	PLoS One	7(10)	e46908	2012
Mayahara H, Ito Y, Morizane C, Ueno H, <u>Okusaka T</u> , et. al.	Salvage chemoradiotherapy after primary chemotherapy for locally advanced pancreatic cancer: a single-institution retrospective analysis.	BMC Cancer	12	609	2012
Ueno H, Ioka T, Ikeda M, <u>Okusaka T</u> , et. al.	Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.	J Clin Oncol	31(13)	1640-8	2013
<u>Ikeda M</u> , Ioka T, Ito Y, Yonemoto N, <u>Okusaka T</u> , et. al.	A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer.	Int J Radiat Oncol Biol Phys	85(1)	163-9	2013
Furuse J, <u>Ishii H</u> , <u>Okusaka T</u>	The Hepatobiliary and Pancreatic Oncology (HBPO) Group of the Japan Clinical Oncology Group (JCOG): history and future direction.	Jpn J Clin Oncol	43(1)	2-7	2013
Suzuki E, <u>Ikeda M</u> , <u>Okusaka T</u> , Nakamori S, et. al.	A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer.	Cancer Chemother Pharmacol	71(5)	1141-6	2013
Umemura S, <u>Mimaki S</u> , Makinoshima H, Tada S, et. al.	Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis.	Journal of Thoracic Oncology	9	1324-31	2014

Takeda A, <u>Fujii H</u> , et. al.	Maximum Standardized Uptake Value on FDG-PET is a Strong Predictor of Overall and Disease-Free Survival for Non-Small-Cell Lung Cancer Patients after Stereotactic Body Radiotherapy	J Thorac Oncol	9 (1)	65-73	2014
Yoshimoto M, Hayakawa T, Mutoh M, <u>Fujii H</u> , et. al.	In vivo SPECT imaging with ¹¹¹ In-DOTA-c(RGDfK) to detect early pancreatic cancer in a hamster pancreatic carcinogenesis model.	J Nucl Med	53(5)	765-71	2012
<u>Fujii H</u> , Yamaguchi M, Inoue K, Mutoh Y, et. al.	In vivo visualization of heterogeneous intratumoral distribution of hypoxia-inducible factor-1 α activity by the fusion of high-resolution SPECT and morphological imaging tests.	J Biomed Biotechnol	2012	262741	2012
Kaburagi T, Takeuchi H, <u>Fujii H</u> , Saikawa Y, et. al.	Initial experience of individualized chemoradiotherapy for superficial esophageal cancers based on the sentinel lymph node concept.	Esophagus	9(3)	147-152	2012
Takeda A, Kunieda E, <u>Fujii H</u> , Yokosuka N, et. al.	Evaluation for local failure by ¹⁸ F-FDG PET/CT in comparison with CT findings after stereotactic body radiotherapy (SBRT) for localized non-small-cell lung cancer.	Lung Cancer	79(3)	248-53	2013
Suzuki C, Blomqvist L, Hatschek T, Carlsson L, <u>Fujii H</u> , et. al.	Impact of the first tumor response at eight weeks on overall survival in metastatic breast cancer patients treated with first-line combination chemotherapy.	Med Oncol	30(1)	415	2013
H. Kuno, H. Onaya, S. Fujii, H. Ojiri, <u>M. Satake</u> , et. al.	Primary staging of laryngeal and hypopharyngeal cancer: CT, MR imaging and dual-energy CT.	European Journal of Radiology	83(1)	e23-e35	2014

M. Ikeda, S. Mitsunaga, S. Shimizu, <u>M.Satake</u> , et al.	Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization.	J Gastroenterol	49	932-940	2014
T. Ishihara, T. Kobayashi, N. Ikeno, <u>M. Satake</u> , et al.	Evaluation of a Near-Infrared-Type Contrast Medium Extravasation Detection System Using a Swine Model.	J Comput Assist Tomogr	38(2)	285-292	2014
M. Sugimoto, S. Takahashi, T. Kobayashi, <u>M. Satake</u> , et al.	Pancreatic perfusion data and post-pancreaticoduodenectomy outcomes.	Journal of Surgical Research	192(2)	441-9	2015
S. Murata, S. Onozawa, T. Mine, <u>M. Satake</u> , et al.	Retrograde-outflow percutaneous isolated hepatic perfusion using cisplatin: A pilot study on pharmacokinetics and feasibility.	Eur Radiol	In Press	DOI 10.1007/s00330-014-3558-2	2015
Ahmed S. Maklad, M.Matsuihiro, H.Suzuki, <u>M.Satake</u> , et al.	Blood vessel-based liver segmentation using the portal phase of an abdominal CT dataset.	Medical Physics	40(11)	113501-1-17	2013
M.Ikeda, T.Okusaka, J.Furuse, <u>M.Satake</u> , et al.	A multi-institutional phase II trial of hepatic arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis.	Cancer Chemother Pharmacol	72	463-470	2013
M.Ikeda, S.Mitsunaga, S.Shimizu, <u>M.Satake</u> , et al.	Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization.	J Gastroenterol	49(5)	932-40	2013
H.Kunoo, H.Onaya, S.Fujii, <u>M.Satake</u> , et al.	Primary staging of laryngeal and hypopharyngeal cancer:CT, MR imaging and dual-energy CT.	European Journal of Radiology	83	e23–e35	2014

Y Akashi, T Oda, Y Ohara, R Miyamoto, <u>M Satake</u> , et. al.	Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that overexpressed neuropilin-1.	Br J CANCER	110(6)	1481-7	2014
Kuno H, Onaya H, Iwata R, Kobayashi T, <u>Satake M</u> , et. al.	Evaluation of cartilage invasion by laryngeal and hypopharyngeal squamous cell carcinoma with dual-energy CT ¹ .	Radiology	265(2)	488-96	2012
<u>Kojima M</u> , Sudo H, Kawauchi J, Takizawa S, et. al.	MicroRNA Markers for the Diagnosis of Pancreatic and Biliary-Tract Cancers.	PLoS One	10	e0118220	2015
Yokota M, <u>Kojima M</u> , Higuchi Y, Nishizawa Y, et. al.	Spread of tumor microenvironment contributes to colonic obstruction through subperitoneal fibroblast activation in colon cancer.	Cancer Sci	In press.	doi:10.1111/cas.12615.	2015
Ueno H, Shirouzu K, Shimazaki H, Kawachi H, <u>Kojima M</u> , et. al.	Histogenesis and prognostic value of myenteric spread in colorectal cancer: a Japanese multi-institutional study.	J Gastroenterol.	49(3)	400-7	2014
Yamada E, Ishii G, Aramaki N, Aokage K, <u>Kojima M</u> , et. al.	Tumor-size-based morphological features of metastatic lymph node tumors from primary lung adenocarcinoma.	Pathol Int.	64(12)	591-600	2014
Saito N, Ito M, Kobayashi A, <u>Kojima M</u> , et. al.	Long-term outcomes after intersphincteric resection for low-lying rectal cancer.	Ann Surg Oncol	21(11)	3608-15	2014
Kaneko K, Yamaguchi H, Saito T, <u>Kojima M</u> , et. al.	Hypoxia imaging endoscopy equipped with laser light source from preclinical live animal study to first-in-human subject research.	PLoS One	9(6)	e99055	2014

Yokota M, <u>Kojima M</u> , Nomura S, Nishizawa Y, et. al.	Clinical impact of elastic lamina invasion in colon cancer: elastic lamina invasion-positive stage II colon cancer is a high-risk equivalent to stage III.	Dis Colon Rectum	57(7)	830-8.	2014
Sato M, <u>Kojima M</u> , Nagatsuma AK, Nakamura, et. al.	Optimal fixation for total preanalytic phase evaluation in pathology laboratories. A comprehensive study including immunohistochemistry, DNA, and mRNA assays.	Pathol Int.	64(5)	209-16	2014
Sugimoto M, Mitsunaga S, Yoshikawa K, <u>Kojima M</u> , et. al.	Prognostic impact of M2 macrophages at neural invasion in patients with invasive ductal carcinoma of the pancreas.	Eur J Cancer.	50(11)	1900-8	2014
Sugimoto M, Takahashi S, <u>Kojima M</u> , Gotohda N, et. al.	What is the nature of pancreatic consistency? Assessment of the elastic modulus of the pancreas and comparison with tactile sensation, histology, and occurrence of postoperative pancreatic fistula after pancreaticoduodenectomy.	Surgery	156(5)	1204-1117	2014
<u>Kojima M</u> , et. al.	Human subperitoneal fibroblast and cancer cell interaction creates microenvironment that enhances tumor progression and metastasis.	PLoS One	9(2)	e88018	2014
<u>Kojima M</u> , et. al.	Pathological diagnostic criterion of blood and lymphatic vessel invasion in colorectal cancer: a framework for developing an objective pathological diagnostic system using the Delphi method, from the Pathology Working Group of the Japanese Society for Cancer of the Colon and Rectum.	Journal of Clinical Pathology	66(7)	551-558	2013

<u>Kojima M</u> , et al.	Practical utility and objectivity: does evaluation of peritoneal elastic laminal invasion in colorectal cancer overcome these contrary problems?	American Journal of Surgical Pathology	38(1)	144-145	2014
Aizawa M, <u>Kojima M</u> , Gotohda N, Fujii S, et. al.	Geminin expression in pancreatic neuroendocrine tumors: possible new marker of malignancy.	Pancreas	41(4)	512-7	2012
Kawamoto Y, Tsuchihara K, Yoshino T, Ogasawara N, <u>Kojima M</u> , et. al.	KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer.	Br J Cancer	107(2)	340-4	2012
Hirayama S, Ishii G, Nagai K, Ono S, <u>Kojima M</u> , et. al.	Prognostic impact of CD204-positive macrophages in lung squamous cell carcinoma: possible contribution of Cd204-positive macrophages to the tumor-promoting microenvironment.	J Thorac Oncol	7(12)	1790-7	2012
Makinoshima H, Ishii G, <u>Kojima M</u> , Fujii S, et. al.	PTPRZ1 regulates calmodulin phosphorylation and tumor progression in small-cell lung carcinoma.	BMC Cancer	12	537	2012
<u>Kojima M</u> , Yokota M, Saito N, Nomura S, et. al.	Elastic laminal invasion in colon cancer: diagnostic utility and histological features.	Front Oncol	2	179	2012
Sugimoto M, Gotohda N, Kato Y, Takahashi S, <u>Kojima M</u> , et. al.	Pancreatic resection for metastatic melanoma originating from the Nasal Cavity: A Case Report and Literature Review.	Anticancer Res	33(2)	567-73	2013

研究成果の刊行に関する一覧表

書籍（日本語）

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
小嶋基寛	腫瘍類似病変	青笹克之	癌診療指針のための病理診断プラクティス 肝・胆・膵腫瘍	中山書店	東京	2014	287-293
柴 知史、 奥坂拓志	膵がん 2. 各論	石岡千加史、 井上 忠夫	エビデンスに基づいたがん薬物療法エキスパートマニュアル	総合医学社	東京	2012	125-30
上野 秀樹、 奥坂拓志	膵癌	泉 孝英	癌診療の現状・今日の診療のためにガイドライン外来診療2013	日経メディカル開発	東京	2013	572-73
土原一哉 松島洸達 三牧幸代	全エクソンリシークエンシング	影山博之	次世代シークエンサー：目的別アドバンストメソッド	秀潤社	東京	2012	56-63

雑誌（日本語）

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
池田公史、江角浩安	何故、牛蒡子か？	胆と膵	36	105-8	2015
佐々木満仁、上野秀樹、林秀幸、他	膵がんに対する術後補助療法のエビデンスと今後の展望	腫瘍内科	12	259-65	2013
森実千種、奥坂拓志、上野秀樹、他	【外科医が知っておくべき癌治療の薬物療法】 抗癌薬各論 胆管癌・膵癌の薬物療法 切除不能・再発癌	外科	75	1369-74	2013

林秀幸, 上野秀樹, 柴知史	【膵・胆道癌薬物療法: 臨床試験を読む!-最新の動向と実地診療へのインパクト-】局所進行または転移性膵癌に対する GEM+S-1 併用療法, S-1 単剤療法, または GEM 単剤療法のランダム化第 Ⅲ 相試験 GEST 試験	胆と膵	34	601-06	2013
奥坂拓志	膵がん. 早期発見・早期治療のためのがん部位別基礎講座	ヘルスアンドライフ 2月号	第3274号		2012
奥坂拓志, 加藤弥菜, 荒井保明, 上嶋一臣	座談会 肝癌薬物治療のこれから -分子標的治療と経動脈治療-	The Liver Cancer Journal	4(2)	17-25	2012
上野秀樹, 奥坂拓志	4. 内科治療の進歩, 1. 膵癌. 特集 膵腫瘍: 診断と治療の進歩	日本内科学会 雑誌	101(1)	29-36	2012
上野秀樹, 奥坂拓志	膵癌の化学療法・化学放射線療法. 特集 膵癌診断の最新トピックス	癌と化学療法	39(3)	357-63	2012
坂本康成, 上野秀樹, 奥坂拓志	膵胆道癌化学療法の最前線. 胆・膵疾患診療の最前線・治療/最新の治療戦略とその成果 -病診連携のために-	Medical Practice	29(1)	140-4	2012
池田公史, 奥坂拓志	肝癌	薬局	63(4)増刊号	1380-5	2012
池田公史, 光永修一, 清水怜, 奥坂拓志, 他	進行肝細胞癌に対するソラフェニブの現状と今後の展望. 進行肝癌治療の現状と今後	日本消化器病 学会雑誌	109(8)	1346-54	2012
多田稔, 奥坂拓志, 古瀬純司, 森田智志	【座談会】膵癌治療の最新展開; タルセバ・ジェムザール・TS-1	肝胆膵	64(2)	269-86	2012
曾根美雪, 荒井保明, 奥坂拓志, 他	医師主導の多施設共同臨床試験における UMIN インターネット症例登録センター (UMIN-INDICE) の活用: 日本腫瘍 IVR 研究グループ (Japan Interventional Radiology in Oncology Study Group: JIVROSG) での評価	がんと化学療法	39(4)	619-23	2012

奥坂拓志	標準治療 選択肢が増え二次治療も可能になった化学療法. 特集 膵臓がん -標準治療と先進治療-	今日の診療のために ガイドライン 外来診療2013	8	14-8	2013
森実千種、奥坂拓志、池田公史	膵消化管神経内分泌腫瘍の内科治療-分子標的薬. 特集：神経内分泌腫瘍を知り尽くす	Mebio	30(4)	88-94	2013
林 秀幸、森実千種、坂本康成、奥坂拓志、他	神経内分泌新生物の化学療法・分子標的治療薬. 特集 消化器神経内分泌腫	臨牀消化器内科	28(1)	113-20	2013
柴 知史、森実千種、林 秀幸、奥坂拓志、他	消化器神経内分泌腫瘍に対する全身化学療法. 特集 消化器癌化学療法-新たなエビデンスを求めて	臨牀消化器内科	28(3)	349-56	2013
藤井博史	III 分子イメージングの臨床への展開 2. がんの分子イメージングの現状と展望	Innervision	29 (7)	63-66	2014
梅田泉、木村禎亮、藤井博史	ニトロイミダゾール類とは異なる集積機序をもつ ^{99m} Tc標識低酸素イメージングプローブの開発	JSMI report	8 (1)	66-69	2014
梅田泉、藤井博史	臨床応用を目指した分子イメージング研究の現状と今後の展望	日本耳鼻咽喉科学会会報	116 (8)	933-940	2013
久野博文、女屋博昭、佐竹光夫	Certificate of Merit 受賞報告 Imaging of Oropharyngeal Cancer: How Can the Radiologist Help with Treatment Planning?	INNERVISION	28(2)	66	2013
佐藤正明、小嶋基寛、永妻晶子、他	パラフィンブロックの長期保存と採取試料の固定までの時間が与えるKi-67免疫染色、DNAとRNAへの影響	診断病理	32(1)	12-17	2015

<u>小嶋基寛</u> 、 <u>落合淳志</u>	大腸癌の最新治療・治癒 に向けた最先端研究・ 大腸癌の浸潤・転移機構	日本臨牀	72(1)	2-6	2014
<u>小嶋基寛</u>	脈管侵襲の評価法と分 類，どうあるべきか	大腸癌 FRONTIER	5	243	2012